A controlled comparison of sertraline and fluoxetine in acute and continuation treatment of major depression

Moffaert, Myriam Van; Bartholomé, F.; Cosyns, Paul; Nayer, A. R. De; Mertens, C

doi:10.1002/hup.470100505

Cited by 46 publications

(30 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Geddes et al (2003) in a meta-analysis of 31 randomized trials-few finding supports significant differences between individual SSRI maintenance therapies. Van Moffaert et al (1995) demonstrated that sertraline and fluoxetine had similar antidepressant efficacy and tolerability for continuation treatment. Other studies showed no significant differences between sertraline and fluvoxamine (Franchini et al, 1997(Franchini et al, , 2000 or between paroxetine and duloxetine (Perahia et al, 2006).…”

Section: Discussionmentioning

confidence: 98%

Prophylactic efficacy of fluoxetine, escitalopram, sertraline, paroxetine, and concomitant psychotherapy in major depressive disorder: Outcome after long-term follow-up

Peselow

Tobia

Karamians

et al. 2015

Psychiatry Research

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 98%

Prophylactic efficacy of fluoxetine, escitalopram, sertraline, paroxetine, and concomitant psychotherapy in major depressive disorder: Outcome after long-term follow-up

Peselow

Tobia

Karamians

et al. 2015

Psychiatry Research

View full text Add to dashboard Cite

“…Indeed, studies have shown that sertraline does provide some of these advantages relative to other SSRIs (Hindmarch et al, 1990;Meara et al, 1995;Thakore et al, 1995;Van Moffaert et al, 1995;Bisserbe et al, 1996;Latimer et al, 1996;Newhouse et al, 1996;Price et al, 1996;Shulman et al, 1996;Zanardi et al, 1996;Hauser and Zesiewicz, 1997;Lane, 1997;MacKay et al, 1997;Mulholland et al, 1997;Waldinger, 1997;Agren et al, 1998;Lane, 1998).…”

Section: Pharmacologymentioning

confidence: 96%

Selective serotonin reuptake inhibitors in affective disorders — I. Basic pharmacology

Goodnick¹,

1998

View full text Add to dashboard Cite

The selective serotonin reuptake inhibitors (SSRIs), citalopram, fluoxetine, fluvoxamine, paroxetine and sertraline, are the result of rational research to find drugs that were as effective as the tricyclic antidepressants but with fewer safety and tolerability problems. The SSRIs selectively and powerfully inhibit serotonin reuptake and result in a potentiation of serotonergic neurotransmission. The property of potent serotonin reuptake appears to give a broad spectrum of therapeutic activity in depression, anxiety, obsessional and impulse control disorders. However, despite the sharing of the same principal mechanism of action, SSRIs are structurally diverse with clear variations in their pharmacodynamic and pharmacokinetic profiles. The potency for serotonin reuptake inhibition varies amongst this group, as does the selectivity for serotonin relative to noradrenaline and dopamine reuptake inhibition. The relative potency of sertraline for dopamine reuptake inhibition differentiates it pharmacologically from other SSRIs. Affinity for neuroreceptors, such as sigma1, muscarinic and 5-HT 2c , also differs widely. Furthermore, the inhibition of nitric oxide synthetase by paroxetine, and possibly other SSRIs, may have significant pharmacodynamic effects. Citalopram and fluoxetine are racemic mixtures of different chiral forms that possess varying pharmacokinetic and pharmacological profiles. Fluoxetine has a long acting and pharmacologically active metabolite. There are important clinical differences among the SSRIs in their pharmacokinetic characteristics. These include differences in their half-lives, linear versus non-linear pharmacokinetics, effect of age on their clearance and their potential to inhibit drug metabolising cytochrome P450 (CYP) isoenzymes. These pharmacological and pharmacokinetic differences underly the increasingly apparent important clinical differences amongst the SSRIs.

show abstract

“…Four head-to-head trials (five publications) provide evidence of moderate strength that the overall efficacy of second-generation antidepressants for maintaining remission does not differ between drugs studied in these trials (Table 1) (13)(14)(15)(16)(17). Comparisons included duloxetine with paroxetine (17), fluoxetine with sertraline (13), fluvoxamine with sertraline (14,15), and trazodone with venlafaxine (16).…”

Section: Comparative Trialsmentioning

confidence: 99%

Meta-analysis of Major Depressive Disorder Relapse and Recurrence With Second-Generation Antidepressants

Hansen¹,

Gaynes²,

Thieda³

et al. 2008

Psychiatric Services

View full text Add to dashboard Cite

Objective-To review data on the efficacy and effectiveness of second-generation antidepressants for preventing major depression relapse and recurrence during continuation and maintenance phase treatment, respectively.Methods-MEDLINE®, EMBASE, and PsychLit; the Cochrane Library; and the International Pharmaceutical Abstracts were searched from January 1980 through April 2007 for reviews, randomized controlled trials, meta-analyses, and observational studies. Two persons independently reviewed abstracts and full text articles using a structured data abstraction form to ensure consistency in appraisal and data extraction.Findings-Four comparative trials and 23 placebo controlled trials that addressed relapse or recurrence prevention were included. Results of comparative trials have not demonstrated statistically significant differences between duloxetine and paroxetine, fluoxetine and sertraline, fluvoxamine and sertraline, and trazodone and venlafaxine. Pooled data for the class of secondgeneration antidepressants compared with placebo suggest a relatively large effect size that persists over time. The number needed to treat to prevent one additional relapse or recurrence is 5 (95% CI 4 to 6). Differences in the length of open-label treatment prior to randomization, drug type, and trial duration did not affect pooled estimates of relapse rates (P = 0.716, P = 0.507, and P = 0.480, aCorresponding author and reprint address:

show abstract

A controlled comparison of sertraline and fluoxetine in acute and continuation treatment of major depression

Cited by 46 publications

References 15 publications

Prophylactic efficacy of fluoxetine, escitalopram, sertraline, paroxetine, and concomitant psychotherapy in major depressive disorder: Outcome after long-term follow-up

Prophylactic efficacy of fluoxetine, escitalopram, sertraline, paroxetine, and concomitant psychotherapy in major depressive disorder: Outcome after long-term follow-up

Selective serotonin reuptake inhibitors in affective disorders — I. Basic pharmacology

Meta-analysis of Major Depressive Disorder Relapse and Recurrence With Second-Generation Antidepressants

Contact Info

Product

Resources

About